NP47825 Multiple Sclerosis Medicines
Estimated value
—
Awarded value
—
Suppliers
9
Lots
2
Published
02 May 2025
Description
Supply of multiple sclerosis medicines to NHS Scotland.
Scope
- Reference
- ocds-h6vhtk-04ce06
- Commercial tool
- Standalone contract
- Contract dates
The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of twenty-one (21) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.
- Main category
- goods
- CPV classifications
- 33600000
- Contract locations
- Scotland
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Technical (Supply Chain) | 5 | quality | — |
| — | 95 | price | — |
Submission & procedure
- Procedure
- Open procedure
Award details· 2 awards
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Lots · 2 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 1 | Glatiramer acetate solution for injection pre-filled syringes, interferon beta-1a, cladribine tablets, ozanimod capsules, and natalizumab | £49.3m | cancelled |
| 2 | Fingolimod capsules, teriflunomide tablets, and dimethyl fumarate capsules | £2.2m | cancelled |
Award 1· 6 suppliers
Awarded —
Award 2· 3 suppliers
Awarded —
Total lots
2
Awarded
2
Estimated total
£51.5m
Awarded total
—
Glatiramer acetate solution for injection pre-filled syringes, interferon beta-1a, cladribine tablets, ozanimod capsules, and natalizumab
Start
—
End
—
Estimated
£49.3m
CPV
Fingolimod capsules, teriflunomide tablets, and dimethyl fumarate capsules
Start
—
End
—
Estimated
£2.2m
CPV
Other contracts from The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
Full notice and award history for this contracting authority is on the buyer profile.
Other contracts awarded to Sandoz Ltd· 10
Cross-buyer view of this supplier's public-sector wins.
| Title | Type | Value | Published |
|---|---|---|---|
| Ustekinumab | contract | — | 15 Jun 2026 |
| NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 | contract | — | 09 Jun 2026 |
| Transitional Drugs 6 | contract | — | 04 Feb 2026 |
| NHS National Generic Pharmaceuticals - Wave 15c | contract | — | 14 Jan 2026 |
| NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025 | contract | — | 01 Aug 2025 |
| NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025 | contract | £47.0m | 29 Jul 2025 |
| NHS Branded Medicines Tranche A - London & SOFE & Adult Influenza National | contract | £9.4m | 24 Jul 2025 |
| NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 1) | contract | £0.02 | 14 May 2024 |
| NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024 | contract | £11.2m | 01 May 2024 |
| NHS National Framework for Transition products commencing 1 May 2024 | contract | £630k | 24 Apr 2024 |